FDA approves Erivedge (vismodegib) capsule
The first medicine for adults with advanced basal cell carcinoma...
30 January 2012 | By
The first medicine for adults with advanced basal cell carcinoma...
List view / Grid view
Hal V. Barron (born 1962) is an American clinician-scientist and drug developer currently serving as president of research and development at Calico. He has served as executive vice president, head of global product development, and chief medical officer of Hoffman-La Roche.
Barron joined Genentech in 1996 as a clinical scientist and was promoted in 2002 to Vice President of Medical Affairs. In 2002 Barron was promoted to vice president of medical affairs and in 2003 he became the senior vice president of development. In 2004 he was appointed chief medical officer and in 2009 he was appointed executive vice president.
Barron’s current academic positions at the University of California, San Francisco include Associate Adjunct Professor of Epidemiology and Biostatistics, and Associate Clinical Professor of Medicine/Cardiology. He has been issued several patents for his work in thrombosis and angiogenesis, and has published more than 90 papers in peer-reviewed scientific journals. He was a member of the board of directors at Alexza Pharmaceuticals.
The first medicine for adults with advanced basal cell carcinoma...
30 January 2012 | By
The first medicine for adults with advanced basal cell carcinoma...
6.1 month improvement in median progression free survival, from 12.4…
8 December 2011 | By Roche
6.1 month improvement in median progression free survival, from 12.4 to 18.5 months...
Results from studies to be presented at SABCS...
30 November 2011 | By Roche
Results from studies to be presented at SABCS...
FDA Commissioner revokes approval of Avastin for treatment of mBC…
18 November 2011 | By Roche
FDA Commissioner revokes approval of Avastin for treatment of mBC in the US...
The vismodegib application has been granted priority review...
9 November 2011 | By Roche
The vismodegib application has been granted priority review...
Phase III trials underway to investigate ocrelizumab in two forms…
20 October 2011 | By Roche
Phase III trials underway to investigate ocrelizumab in two forms of MS...
Phase III study of a quicker route of administration shows…
17 October 2011 | By Roche
Phase III study of a quicker route of administration shows comparable results to intravenous Herceptin...
Phase II study TDM4450g results announced...
25 September 2011 | By Roche
Phase II study TDM4450g results announced...
First and only personalized medicine shown to help people with…
17 August 2011 | By Roche
First and only personalized medicine shown to help people with BRAF V600E mutation-positive metastatic melanoma...
The European Commission has approved the use of RoACTEMRA (tocilizumab)...
3 August 2011 | By Roche
The European Commission has approved the use of RoACTEMRA (tocilizumab)...
Roche plans to seek approval with Health Authorities based on…
15 July 2011 | By Roche
Roche plans to seek approval with Health Authorities based on encouraging results...
Pivotal Phase II study with vismodegib showed positive results in…
20 June 2011 | By Roche
Pivotal Phase II study with vismodegib showed positive results in people with advanced advanced basal cell carcinoma.
Roche announced that a Phase III study (BRIM3) showed vemurafenib…
5 June 2011 | By Roche
Roche announced that a Phase III study (BRIM3) showed vemurafenib (RG7204, PLX4032) significantly improved overall survival in people with previously untreated BRAF V600 mutation...
Roche announced results from OCEANS, a phase III study evaluating…
4 June 2011 | By Roche
Roche announced results from OCEANS, a phase III study evaluating Avastin (bevacizumab) in combination with chemotherapy (gemcitabine and carboplatin)...
Genentech, and Biogen Idec announced today that the FDA approved…
19 April 2011 | By Biogen Idec
Genentech, and Biogen Idec announced today that the FDA approved Rituxan® (rituximab)...